Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | DHODH | Q02127 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | POLB | P06746 | 3/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4996880 | 0.94 | DHODH (0.49) | MAPTALDH1A1KDM4EDHODHKMT2A | |
| SCHEMBL4991820 | 0.93 | MAPT (0.43) | MAPTALDH1A1MAPK1KDM4EKMT2A | |
| SCHEMBL4991409 | 0.93 | MAPT (0.49) | MAPTALDH1A1MAPK1KDM4EDHODH | |
| SCHEMBL4996507 | 0.89 | MAPT (0.49) | MAPTALDH1A1DHODHKMT2ATDP1 | |
| SCHEMBL4999646 | 0.88 | HSD17B1 (0.39) | MAPTALDH1A1KDM4EKMT2APOLB | |
| SCHEMBL4991744 | 0.88 | AMY1A (0.46) | MAPTALDH1A1MAPK1KDM4EDHODH | |
| SCHEMBL4996040 | 0.87 | CFTR (0.47) | MAPTDHODHKMT2AADORA2BSMN1; SMN2 | |
| SCHEMBL4991753 | 0.87 | DHODH (0.50) | MAPTALDH1A1MAPK1DHODHKMT2A | |
| SCHEMBL4997423 | 0.86 | SMN1; SMN2 (0.49) | MAPTALDH1A1MAPK1KDM4EDHODH | |
| SCHEMBL5002321 | 0.86 | CDC7 (0.47) | MAPTALDH1A1SMN1; SMN2HSD17B10HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080113971-A1 | PYRAZOLE COMPOUNDS AS PROTEIN KINASE INHIBITORS | HANAU CATHLEEN E | 2008-05-15 | — | — | US | disclosed |
| US-20080113971-A1 | PYRAZOLE COMPOUNDS AS PROTEIN KINASE INHIBITORS | HANAU CATHLEEN E | 2008-05-15 | — | — | US | disclosed |
| US-20080113971-A1 | PYRAZOLE COMPOUNDS AS PROTEIN KINASE INHIBITORS | HANAU CATHLEEN E | 2008-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080113971-A1 | PYRAZOLE COMPOUNDS AS PROTEIN KINASE INHIBITORS | MKNK2, MAPKAPK2, MAP3K2 | MAPT 1363/4885ALDH1A1 4153/4885MAPK1 41/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.